Date: Jun 1<sup>st</sup>, 2021 Your Name: Tianfu Li Manuscript Title: Sequential versus concurrent adjuvant chemo-endocrine therapy for HR+ early breast cancer: a systematic review and Bayesian network meta-analysis Manuscript number (if known):\_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |  | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed)<br>Time frame: Since the initial | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|--|---|---|
| 1 | All support for the present<br>manuscript (e.g., funding,<br>provision of study materials,<br>medical writing, article<br>processing charges, etc.)<br><b>No time limit for this item.</b> | _XNone  |   |
|   |  | Time frame: past  | 36 months   |
| 2 | Grants or contracts from<br>any entity (if not indicated<br>in item #1 above).   | _XNone  |   |
| 3 | Royalties or licenses  | _XNone  |   |
| 4 | Consulting fees  | _XNone  |   |

| 5  | Payment or honoraria for lectures, presentations,                       | _XNone  |  |
|----|---|---------|--|
|    |   |         |  |
|    | speakers bureaus,   |         |  |
|    | manuscript writing or<br>educational events                             |         |  |
| 6  | Payment for expert  | X None  |  |
| 0  | testimony   |         |  |
|    | testimony   |         |  |
| 7  | Support for attending   | X None  |  |
|    | meetings and/or travel  |         |  |
|    |   |         |  |
|    |   |         |  |
| 8  | Patents planned, issued or  | _XNone  |  |
|    | pending   |         |  |
|    |   |         |  |
| 9  | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board | _XNone  |  |
|    |   |         |  |
| 10 |   | V. Nere |  |
| 10 | Leadership or fiduciary role in other board, society,                   | _XNone  |  |
|    | committee or advocacy   |         |  |
|    | group, paid or unpaid   |         |  |
| 11 | Stock or stock options  | X None  |  |
|    |   |         |  |
|    |   |         |  |
| 12 | Receipt of equipment,   | _XNone  |  |
|    | materials, drugs, medical   |         |  |
|    | writing, gifts or other   |         |  |
| 12 | services  | V. Neve |  |
| 13 | Other financial or non-   | _XNone  |  |
|    | financial interests   |         |  |
|    |   |         |  |

None.

Please place an "X" next to the following statement to indicate your agreement:

Date: Jun 1<sup>st</sup>, 2021 Your Name: Zhen Shan Manuscript Title: Sequential versus concurrent adjuvant chemo-endocrine therapy for HR+ early breast cancer: a systematic review and Bayesian network meta-analysis Manuscript number (if known):\_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |  | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed)<br>Time frame: Since the initial | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|--|---|---|
| 1 | All support for the present<br>manuscript (e.g., funding,<br>provision of study materials,<br>medical writing, article<br>processing charges, etc.)<br><b>No time limit for this item.</b> | _XNone  |   |
|   |  | Time frame: past  | 36 months   |
| 2 | Grants or contracts from<br>any entity (if not indicated<br>in item #1 above).   | _XNone  |   |
| 3 | Royalties or licenses  | _XNone  |   |
| 4 | Consulting fees  | _XNone  |   |

| 5  | Payment or honoraria for lectures, presentations,                       | _XNone  |  |
|----|---|---------|--|
|    |   |         |  |
|    | speakers bureaus,   |         |  |
|    | manuscript writing or<br>educational events                             |         |  |
| 6  | Payment for expert  | X None  |  |
| 0  | testimony   |         |  |
|    | testimony   |         |  |
| 7  | Support for attending   | X None  |  |
|    | meetings and/or travel  |         |  |
|    |   |         |  |
|    |   |         |  |
| 8  | Patents planned, issued or  | _XNone  |  |
|    | pending   |         |  |
|    |   |         |  |
| 9  | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board | _XNone  |  |
|    |   |         |  |
| 10 |   | V. Nere |  |
| 10 | Leadership or fiduciary role in other board, society,                   | _XNone  |  |
|    | committee or advocacy   |         |  |
|    | group, paid or unpaid   |         |  |
| 11 | Stock or stock options  | X None  |  |
|    |   |         |  |
|    |   |         |  |
| 12 | Receipt of equipment,   | _XNone  |  |
|    | materials, drugs, medical   |         |  |
|    | writing, gifts or other   |         |  |
| 12 | services  | V. Neve |  |
| 13 | Other financial or non-   | _XNone  |  |
|    | financial interests   |         |  |
|    |   |         |  |

None.

Please place an "X" next to the following statement to indicate your agreement:

Date: Jun 1<sup>st</sup>, 2021 Your Name: Yawei Shi Manuscript Title: Sequential versus concurrent adjuvant chemo-endocrine therapy for HR+ early breast cancer: a systematic review and Bayesian network meta-analysis Manuscript number (if known):\_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |  | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed)<br>Time frame: Since the initial | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|--|---|---|
| 1 | All support for the present<br>manuscript (e.g., funding,<br>provision of study materials,<br>medical writing, article<br>processing charges, etc.)<br><b>No time limit for this item.</b> | _XNone  |   |
|   |  | Time frame: past  | 36 months   |
| 2 | Grants or contracts from<br>any entity (if not indicated<br>in item #1 above).   | _XNone  |   |
| 3 | Royalties or licenses  | _XNone  |   |
| 4 | Consulting fees  | _XNone  |   |

| 5  | Payment or honoraria for lectures, presentations,                       | _XNone  |  |
|----|---|---------|--|
|    |   |         |  |
|    | speakers bureaus,   |         |  |
|    | manuscript writing or<br>educational events                             |         |  |
| 6  | Payment for expert  | X None  |  |
| 0  | testimony   |         |  |
|    | testimony   |         |  |
| 7  | Support for attending   | X None  |  |
|    | meetings and/or travel  |         |  |
|    |   |         |  |
|    |   |         |  |
| 8  | Patents planned, issued or  | _XNone  |  |
|    | pending   |         |  |
|    |   |         |  |
| 9  | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board | _XNone  |  |
|    |   |         |  |
| 10 |   | V. Nere |  |
| 10 | Leadership or fiduciary role in other board, society,                   | _XNone  |  |
|    | committee or advocacy   |         |  |
|    | group, paid or unpaid   |         |  |
| 11 | Stock or stock options  | X None  |  |
|    |   |         |  |
|    |   |         |  |
| 12 | Receipt of equipment,   | _XNone  |  |
|    | materials, drugs, medical   |         |  |
|    | writing, gifts or other   |         |  |
| 12 | services  | V. Neve |  |
| 13 | Other financial or non-   | _XNone  |  |
|    | financial interests   |         |  |
|    |   |         |  |

None.

Please place an "X" next to the following statement to indicate your agreement:

Date: Jun 1<sup>st</sup>, 2021 Your Name: Xiaying Kuang Manuscript Title: Sequential versus concurrent adjuvant chemo-endocrine therapy for HR+ early breast cancer: a systematic review and Bayesian network meta-analysis Manuscript number (if known):\_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |  | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed)<br>Time frame: Since the initial | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|--|---|---|
| 1 | All support for the present<br>manuscript (e.g., funding,<br>provision of study materials,<br>medical writing, article<br>processing charges, etc.)<br><b>No time limit for this item.</b> | _XNone  |   |
|   |  | Time frame: past  | 36 months   |
| 2 | Grants or contracts from<br>any entity (if not indicated<br>in item #1 above).   | _XNone  |   |
| 3 | Royalties or licenses  | _XNone  |   |
| 4 | Consulting fees  | _XNone  |   |

| 5  | Payment or honoraria for lectures, presentations,                       | _XNone  |  |
|----|---|---------|--|
|    |   |         |  |
|    | speakers bureaus,   |         |  |
|    | manuscript writing or<br>educational events                             |         |  |
| 6  | Payment for expert  | X None  |  |
| 0  | testimony   |         |  |
|    | testimony   |         |  |
| 7  | Support for attending   | X None  |  |
|    | meetings and/or travel  |         |  |
|    |   |         |  |
|    |   |         |  |
| 8  | Patents planned, issued or  | _XNone  |  |
|    | pending   |         |  |
|    |   |         |  |
| 9  | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board | _XNone  |  |
|    |   |         |  |
| 10 |   | V. Nere |  |
| 10 | Leadership or fiduciary role in other board, society,                   | _XNone  |  |
|    | committee or advocacy   |         |  |
|    | group, paid or unpaid   |         |  |
| 11 | Stock or stock options  | X None  |  |
|    |   |         |  |
|    |   |         |  |
| 12 | Receipt of equipment,   | _XNone  |  |
|    | materials, drugs, medical   |         |  |
|    | writing, gifts or other   |         |  |
| 12 | services  | V. Neve |  |
| 13 | Other financial or non-   | _XNone  |  |
|    | financial interests   |         |  |
|    |   |         |  |

None.

Please place an "X" next to the following statement to indicate your agreement:

Date: Jun 1<sup>st</sup>, 2021 Your Name: Liang Yu Manuscript Title: Sequential versus concurrent adjuvant chemo-endocrine therapy for HR+ early breast cancer: a systematic review and Bayesian network meta-analysis Manuscript number (if known):\_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |  | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed)<br>Time frame: Since the initial | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|--|---|---|
| 1 | All support for the present<br>manuscript (e.g., funding,<br>provision of study materials,<br>medical writing, article<br>processing charges, etc.)<br><b>No time limit for this item.</b> | _XNone  |   |
|   |  | Time frame: past  | 36 months   |
| 2 | Grants or contracts from<br>any entity (if not indicated<br>in item #1 above).   | _XNone  |   |
| 3 | Royalties or licenses  | _XNone  |   |
| 4 | Consulting fees  | _XNone  |   |

| 5  | Payment or honoraria for lectures, presentations,                       | _XNone  |  |
|----|---|---------|--|
|    |   |         |  |
|    | speakers bureaus,   |         |  |
|    | manuscript writing or<br>educational events                             |         |  |
| 6  | Payment for expert  | X None  |  |
| 0  | testimony   |         |  |
|    | testimony   |         |  |
| 7  | Support for attending   | X None  |  |
|    | meetings and/or travel  |         |  |
|    |   |         |  |
|    |   |         |  |
| 8  | Patents planned, issued or  | _XNone  |  |
|    | pending   |         |  |
|    |   |         |  |
| 9  | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board | _XNone  |  |
|    |   |         |  |
| 10 |   | V. Nere |  |
| 10 | Leadership or fiduciary role in other board, society,                   | _XNone  |  |
|    | committee or advocacy   |         |  |
|    | group, paid or unpaid   |         |  |
| 11 | Stock or stock options  | X None  |  |
|    |   |         |  |
|    |   |         |  |
| 12 | Receipt of equipment,   | _XNone  |  |
|    | materials, drugs, medical   |         |  |
|    | writing, gifts or other   |         |  |
| 12 | services  | V. Neve |  |
| 13 | Other financial or non-   | _XNone  |  |
|    | financial interests   |         |  |
|    |   |         |  |

None.

Please place an "X" next to the following statement to indicate your agreement:

Date: Jun 1<sup>st</sup>, 2021 Your Name: Shou-Ching Tang Manuscript Title: Sequential versus concurrent adjuvant chemo-endocrine therapy for HR+ early breast cancer: a systematic review and Bayesian network meta-analysis Manuscript number (if known):\_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |  | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed)<br>Time frame: Since the initial | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|--|---|---|
| 1 | All support for the present<br>manuscript (e.g., funding,<br>provision of study materials,<br>medical writing, article<br>processing charges, etc.)<br><b>No time limit for this item.</b> | _XNone  |   |
|   |  | Time frame: past  | 36 months   |
| 2 | Grants or contracts from<br>any entity (if not indicated<br>in item #1 above).   | _XNone  |   |
| 3 | Royalties or licenses  | _XNone  |   |
| 4 | Consulting fees  | _XNone  |   |

| 5  | Payment or honoraria for lectures, presentations,                       | _XNone  |  |
|----|---|---------|--|
|    |   |         |  |
|    | speakers bureaus,   |         |  |
|    | manuscript writing or<br>educational events                             |         |  |
| 6  | Payment for expert  | X None  |  |
| 0  | testimony   |         |  |
|    | testimony   |         |  |
| 7  | Support for attending   | X None  |  |
|    | meetings and/or travel  |         |  |
|    |   |         |  |
|    |   |         |  |
| 8  | Patents planned, issued or  | _XNone  |  |
|    | pending   |         |  |
|    |   |         |  |
| 9  | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board | _XNone  |  |
|    |   |         |  |
| 10 |   | V. Nere |  |
| 10 | Leadership or fiduciary role in other board, society,                   | _XNone  |  |
|    | committee or advocacy   |         |  |
|    | group, paid or unpaid   |         |  |
| 11 | Stock or stock options  | X None  |  |
|    |   |         |  |
|    |   |         |  |
| 12 | Receipt of equipment,   | _XNone  |  |
|    | materials, drugs, medical   |         |  |
|    | writing, gifts or other   |         |  |
| 12 | services  | V. Neve |  |
| 13 | Other financial or non-   | _XNone  |  |
|    | financial interests   |         |  |
|    |   |         |  |

None.

Please place an "X" next to the following statement to indicate your agreement:

Date: Jun 1<sup>st</sup>, 2021 Your Name: Nan Shao Manuscript Title: Sequential versus concurrent adjuvant chemo-endocrine therapy for HR+ early breast cancer: a systematic review and Bayesian network meta-analysis Manuscript number (if known):\_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |  | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed)<br>Time frame: Since the initial | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |  |  |
|---|--|---|---|--|--|
| 1 | All support for the present<br>manuscript (e.g., funding,<br>provision of study materials,<br>medical writing, article<br>processing charges, etc.)<br><b>No time limit for this item.</b> | _XNone  |   |  |  |
|   | Time frame: past 36 months   |   |   |  |  |
| 2 | Grants or contracts from<br>any entity (if not indicated<br>in item #1 above).   | _XNone  |   |  |  |
| 3 | Royalties or licenses  | _XNone  |   |  |  |
| 4 | Consulting fees  | _XNone  |   |  |  |

| 5  | Payment or honoraria for lectures, presentations,                                 | _XNone  |  |
|----|---|---------|--|
|    |   |         |  |
|    | speakers bureaus,   |         |  |
|    | manuscript writing or<br>educational events                                       |         |  |
| 6  | Payment for expert  | X None  |  |
| 0  | testimony   |         |  |
|    | testimony   |         |  |
| 7  | Support for attending   | X None  |  |
|    | meetings and/or travel  |         |  |
|    |   |         |  |
|    |   |         |  |
| 8  | Patents planned, issued or  | _XNone  |  |
|    | pending   |         |  |
|    |   |         |  |
| 9  | Participation on a Data   | _XNone  |  |
|    | Safety Monitoring Board or  |         |  |
| 10 | Advisory Board  | V. Nere |  |
| 10 | Leadership or fiduciary role<br>in other board, society,<br>committee or advocacy | _XNone  |  |
|    |   |         |  |
|    | group, paid or unpaid   |         |  |
| 11 | Stock or stock options  | X None  |  |
|    |   |         |  |
|    |   |         |  |
| 12 | Receipt of equipment,<br>materials, drugs, medical                                | _XNone  |  |
|    |   |         |  |
|    | writing, gifts or other   |         |  |
| 12 | services  | V. Neve |  |
| 13 | Other financial or non-<br>financial interests                                    | _XNone  |  |
|    |   |         |  |
|    |   |         |  |

None.

Please place an "X" next to the following statement to indicate your agreement:

Date: Jun 1<sup>st</sup>, 2021 Your Name: Ying Lin Manuscript Title: Sequential versus concurrent adjuvant chemo-endocrine therapy for HR+ early breast cancer: a systematic review and Bayesian network meta-analysis Manuscript number (if known):\_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |  | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed)<br>Time frame: Since the initial | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |  |  |
|---|--|---|---|--|--|
| 1 | All support for the present<br>manuscript (e.g., funding,<br>provision of study materials,<br>medical writing, article<br>processing charges, etc.)<br><b>No time limit for this item.</b> | _XNone  |   |  |  |
|   | Time frame: past 36 months   |   |   |  |  |
| 2 | Grants or contracts from<br>any entity (if not indicated<br>in item #1 above).   | _XNone  |   |  |  |
| 3 | Royalties or licenses  | _XNone  |   |  |  |
| 4 | Consulting fees  | _XNone  |   |  |  |

| 5  | Payment or honoraria for lectures, presentations,                                 | _XNone  |  |
|----|---|---------|--|
|    |   |         |  |
|    | speakers bureaus,   |         |  |
|    | manuscript writing or<br>educational events                                       |         |  |
| 6  | Payment for expert  | X None  |  |
| 0  | testimony   |         |  |
|    | testimony   |         |  |
| 7  | Support for attending   | X None  |  |
|    | meetings and/or travel  |         |  |
|    |   |         |  |
|    |   |         |  |
| 8  | Patents planned, issued or  | _XNone  |  |
|    | pending   |         |  |
|    |   |         |  |
| 9  | Participation on a Data   | _XNone  |  |
|    | Safety Monitoring Board or  |         |  |
| 10 | Advisory Board  | V. Nere |  |
| 10 | Leadership or fiduciary role<br>in other board, society,<br>committee or advocacy | _XNone  |  |
|    |   |         |  |
|    | group, paid or unpaid   |         |  |
| 11 | Stock or stock options  | X None  |  |
|    |   |         |  |
|    |   |         |  |
| 12 | Receipt of equipment,<br>materials, drugs, medical                                | _XNone  |  |
|    |   |         |  |
|    | writing, gifts or other   |         |  |
| 12 | services  | V. Neve |  |
| 13 | Other financial or non-<br>financial interests                                    | _XNone  |  |
|    |   |         |  |
|    |   |         |  |

None.

Please place an "X" next to the following statement to indicate your agreement: